Biomarin Pharmaceutical

Yahoo Finance • 7 days ago

Notable healthcare headlines for the week: Apellis, Centessa, and UnitedHealth in focus

Wall Street’s major market averages ended mixed on Thursday as markets assessed President Donald Trump’s address to the nation and the latest developments in the Middle East conflict. The tech-focused Nasdaq Composite finished +0.1%. At t... Full story

Yahoo Finance • 13 days ago

BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations

We recently compiled a list of the 10 Quality Value Stocks Likely to Make a Comeback According to Analysts. BioMarin Pharmaceutical Inc. is among the best value stocks to invest in. TheFly reported on March 16 that Wells Fargo maintained... Full story

Yahoo Finance • 23 days ago

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

On February 17, 2026, Boone Capital Management sold out its entire Cogent Biosciences(NASDAQ:COGT) stake, liquidating 945,042 shares previously worth $13.57 million. What happened According to an SEC filing dated February 17, 2026, Boone... Full story

Yahoo Finance • 23 days ago

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

On February 17, 2026, Boone Capital Management disclosed a new position in Tyra Biosciences(NASDAQ:TYRA), acquiring 398,482 shares worth $10.48 million at quarter’s end. What happened According to a Securities and Exchange Commission (SE... Full story

Yahoo Finance • 25 days ago

BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Cheap Stocks to Buy for High Returns in 2026. On March 12, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released positive data from ongoing trials of VOXZOGO, which is the company’s ap... Full story

Yahoo Finance • 28 days ago

Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?

What happened According to a U.S. Securities and Exchange Commission (SEC) filing dated February 17, 2026, Boone Capital Management established a new position in HealthEquity by purchasing 212,856 shares. The reported value of the transac... Full story

Yahoo Finance • last month

BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients

On Friday, the U.S. Food and Drug Administration (FDA) approved BioMarin Pharmaceutical Inc.’ssupplemental application for Palynziq (pegvaliase-pqpz), a treatment for phenylketonuria (PKU) in adolescents aged 12 and older. FDA’s Expanded... Full story

Yahoo Finance • last month

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing

Palo Alto Investors LP reported a buy of 41,303 shares of PTC Therapeutics(NASDAQ:PTCT) in its February 17, 2026, SEC filing, with an estimated transaction value of $3.00 million based on quarterly average pricing. What Happened Accordin... Full story

Yahoo Finance • last month

Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

Absci Corporation Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci’s... Full story

Yahoo Finance • last month

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing

Key Points 209,523-share increase in Dyne Therapeutics; estimated transaction value $3.97 million (based on quarterly average pricing) Quarter-end position in Dyne Therapeutics rose $12.82 million in value, reflecting both trading and sto... Full story

Yahoo Finance • last month

Bernstein Lifts PT on BioMarin Pharmaceutical (BMRN) to $94 From $90, Here’s Why

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, Bernstein lifted the price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $94 from $90 and maintaine... Full story

Yahoo Finance • last month

FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for PALYNZIQ (pegvaliase-pqpz) to include pediatric patients... Full story

Yahoo Finance • last month

Catalyst Watch: Jobs report, new Apple products, and a spotlight on software

[New York Stock Exchange] Selcuk Oner/iStock Editorial via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock pric... Full story

Yahoo Finance • 2 months ago

What Makes BioMarin (BMRN) so Attractive

BioMarin Pharmaceutical (NASDAQ:BMRN) is one of the 17 biotechnology stocks with more than 50% upside. As of February 12 closing, BioMarin Pharmaceutical (NASDAQ:BMRN) carried a moderately bullish analyst sentiment. Of the 15 analysts cov... Full story

Yahoo Finance • 2 months ago

BioMarin Debt Deal And VOXZOGO Approval Recast Rare Disease Outlook

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BioMarin Pharmaceutical (NasdaqGS:BMRN) has closed a large debt offering to help fund its pending acquisition of Amicus The... Full story

Yahoo Finance • 2 months ago

Pharma companies left out of Trump's drug-pricing deals look for way in

By Michael Erman SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U.S. drug pricing are looking to craft their own deals in an attempt to avoid potentiall... Full story

Yahoo Finance • 2 months ago

Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million

Precedence Research Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and CRISPR therapeutics market, highlighting key company performance, pipeline developments, and gover... Full story

Yahoo Finance • 2 months ago

Veeva Systems Inc. (VEEV): Balancing Analyst Skepticism with Innovation and Strategic Partnerships

Veeva Systems (NYSE:VEEV) is one of the best 52-week low blue-chip stocks to buy right now. On January 29, Veeva Systems (NYSE:VEEV) unveiled Veeva eSource, a new Veeva SiteVault tailored to eliminate manual clinical trial processes and in... Full story

Yahoo Finance • 4 months ago

BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push

BioMarin Pharmaceutical has agreed to buy rare disease biotech Amicus Therapeutics, adding three approved or late-stage lysosomal storage disorder therapies to its portfolio. Under the terms of the agreement, BioMarin will pay cash for al... Full story

Yahoo Finance • 4 months ago

Key deals this week: Trump Media & Technology, Howard Hughes, BioMarin Pharmaceutical and more

[Documents about mergers and acquisitions m&a with a pen.] designer491 Here's a list of key deals reported across sectors this week: * BioMarin Pharmaceutical (BMRN [https://seekingalpha.com/symbol/BMRN]) has agreed to acquire [https:/... Full story